Litecoin Could See ETFs Before Solana & XRP – As Sui and Remittix Tipped For Huge Gains In 2025
Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, after the company posted better-than-expected fourth-quarter earnings, boosted by strong demand for a new formulation of its blockbuster eye drug Eylea.
